Compare

MapLight Therapeutics/$MPLT

1D1W1M3M6MYTD1Y5YMAX

About MapLight Therapeutics

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
Ticker
$MPLT
Sector
Health
Primary listing
NASDAQ
Employees
133
Headquarters
Redwood City, United States
Website
www.maplightrx.com

MPLT Metrics

BasicAdvanced
$373M
-
-$7.42
-
-

What the Analysts think about MPLT

Analyst ratings (Buy, Hold, Sell) for MapLight Therapeutics stock.
Analyst projections of the future price of MapLight Therapeutics stock.

Bulls say / Bears say

The twice-daily dose cleared ZEPHYR’s five-week primary endpoint, with a 4.5-point PANSS improvement versus placebo (p=0.015); several key secondary measures also improved. This gives MapLight a credible clinical basis to pursue Phase 3 in schizophrenia. (GlobeNewswire)
The twice-daily regimen had a low 2% rate of GI-related discontinuation in ZEPHYR, giving the drug a possible tolerability advantage in a class where stomach side effects can limit use. Better tolerability could help differentiate it, though the comparison with rival drugs is across separate trials. (BioSpace, GlobeNewswire)
ML-007C-MA is also being tested in Alzheimer’s disease psychosis, with Phase 2 VISTA results expected in the second half of 2027 and FDA Fast Track status. MapLight says its cash and recent $150 million placement should fund VISTA and planned schizophrenia trials through 2028. (MapLight Therapeutics)
The once-daily dose failed to significantly improve symptoms in ZEPHYR, removing the hoped-for convenience edge over a twice-daily competitor. Reuters reported that the mixed readout sent MapLight shares sharply lower. (Reuters)
Schizophrenia efficacy rests on a Phase 2 result and still needs confirmation in another Phase 3 trial, with results expected in 2028. That leaves a long wait and a risk that the benefit is not replicated or development is delayed. (MapLight Therapeutics)
MapLight’s autism candidate ML-004 missed the Phase 2 IRIS primary endpoint, with encouraging findings limited to subgroup analyses. This weakens the value of the pipeline beyond its lead schizophrenia and Alzheimer’s psychosis programme. (Endpoints, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.

MPLT Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

MPLT Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing MPLT

Funds
Fund name
Fund size
$MPLT weighting
SPDR Russell 2000 US Small Cap€R2US
$5.3B0.00%
SPDR Russell 2000 US Small Cap£R2SC
$5.3B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.